Cargando…

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma

Rituximab maintenance (RM) prolongs the progression-free survival (PFS) of responding patients with follicular lymphoma (FL), but the maintenance efficacy in different Follicular Lymphoma International Prognostic Index (FLIPI) risk group is still confusing. We performed a retrospective analysis of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ru, Wang, Tingyu, Lyv, Rui, Wang, Yi, Yu, Ying, Yan, Yuting, Sun, Qi, Xiong, Wenjie, Liu, Wei, Sui, Weiwei, Huang, Wenyang, Wang, Huijun, Li, Chengwen, Wang, Jun, Zou, Dehui, An, Gang, Wang, Jianxiang, Qiu, Lugui, Yi, Shuhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205248/ https://www.ncbi.nlm.nih.gov/pubmed/37228779 http://dx.doi.org/10.1097/BS9.0000000000000144

Ejemplares similares

Maintenance rituximab in Veterans with follicular lymphoma
por: Halwani, Ahmad S., et al.
Publicado: (2020)

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma
Publicado: (2023)

Rituximab maintenance therapy of follicular lymphoma in clinical practice
por: Dührsen, Ulrich, et al.
Publicado: (2018)

Cytogenetic aberrations of lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia in Chinese patients
por: Xiong, Wenjie, et al.
Publicado: (2023)

Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma
por: Buchegger, Franz, et al.
Publicado: (2011)

Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma
por: Aguiar-Bujanda, David, et al.
Publicado: (2015)

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
por: Kim, Hee Kyung, et al.
Publicado: (2020)

Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma
por: Yi, Shuhua, et al.
Publicado: (2022)

Follicular Lymphoma in China: Systematic Evaluation of Follicular Lymphoma Prognostic Models
por: Li, Yanan, et al.
Publicado: (2022)

Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
por: Yan, Yuting, et al.
Publicado: (2023)

P1162: FRONT-LINE RISK-ADAPTED THERAPY PRESENTED FAVORABLE OUTCOMES FOR YOUNG PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A CONSECUTIVE COHORT IN CHINA
por: Zou, Hesong, et al.
Publicado: (2023)

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin’s lymphoma: the evidence of its therapeutic value
por: Ardeshna, Kirit M.
Publicado: (2007)

Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Follicular Lymphoma
por: Yavaşoğlu, İrfan
Publicado: (2015)

Follicular lymphoma
por: Leich, Ellen
Publicado: (2019)

The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States
por: Nastoupil, Loretta J, et al.
Publicado: (2014)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020)

High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival
por: Yi, Shuhua, et al.
Publicado: (2015)

Rituximab pharmacokinetics in ascites and serum in the treatment of follicular lymphoma with massive ascites
por: Hiroshima, Yuki, et al.
Publicado: (2012)

Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
por: Subramanian, Janakiraman, et al.
Publicado: (2017)

The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
por: Fowler, Nathan H., et al.
Publicado: (2020)

A rare face of follicular lymphoma: reverse variant of follicular lymphoma
por: Maskey, Ninu, et al.
Publicado: (2020)

Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
por: Yelvington, Bradley J.
Publicado: (2018)

Minimal residual disease status improved the response evaluation in patients with Waldenström’s macroglobulinemia
por: Xiong, Wenjie, et al.
Publicado: (2023)

BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase
por: Zou, Dehui, et al.
Publicado: (2017)

Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma: A NICE Single Technology Appraisal
por: Greenhalgh, Janette, et al.
Publicado: (2013)

A Case of Fulminant Hepatitis due to Echovirus 9 in a Patient on Maintenance Rituximab Therapy for Follicular Lymphoma
por: Morgan, Ceri, et al.
Publicado: (2015)

Mesenteric follicular lymphoma
por: Nishimura, Yoshito, et al.
Publicado: (2019)

FOLLICULAR LYMPHOMA OF THE RECTUM
por: Konstantinidou, Sevasti, et al.
Publicado: (2020)

Follicular lymphoma genomics
por: Kumar, Emil, et al.
Publicado: (2019)

The pathobiology of follicular lymphoma
por: Carreras, Joaquim
Publicado: (2023)

Colorectal follicular lymphoma: A case report
por: Wang, Mei-Lian, et al.
Publicado: (2019)

Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
por: Hornberger, John, et al.
Publicado: (2008)

Follicular B Cell Lymphoma with Accompanying Ischemic Gastritis Completely Resolved by Rituximab
por: Tariq, Anam, et al.
Publicado: (2017)

Follicular Lymphomas of Oral Region Treated by Rituximab Monotherapy: About Two Cases
por: Montaner, Sylvain, et al.
Publicado: (2018)

Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma
por: Spencer, Scott J, et al.
Publicado: (2021)

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2022)

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
por: Bachy, Emmanuel, et al.
Publicado: (2019)

PB2070: EFFICACY OF RITUXIMAB MAINTENANCE THERAPY IN ADVANCED-STAGE FOLLICULAR LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE STUDY.
por: Amorós, C., et al.
Publicado: (2022)

Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance
por: Durot, Carole, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ejopd9461i3eknvbn34v9ehtkl